Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.

被引：0
|
作者：
Vardell, Victoria
Tantravahi, Srinivas Kiran
机构：
[1] Univ Utah, Dept Hematol & Hematol Malignancies, Salt Lake City, UT USA
[2] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11187
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
    Kockerols, Camille C. B.
    Geelen, Inge
    Levin, Mark-David
    Janssen, Jeroen J. W. M.
    Dinmohamed, Avinash G.
    Hoogendoorn, Mels
    Cornelissen, Jan J.
    Westerweel, Peter E.
    HAEMATOLOGICA, 2022, 107 (08) : 1940 - 1943
  • [32] Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
    Sasaki, Koji
    Kantarjian, Hagop M.
    Jain, Preetesh
    Jabbour, Elias J.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Takahashi, Koichi
    Pemmaraju, Naveen
    Daver, Naval
    Pierce, Sherry A.
    O'Brien, Susan M.
    Cortes, Jorge E.
    CANCER, 2016, 122 (02) : 238 - 248
  • [33] Allogeneic stem cell transplantation for chronic myeloid leukemia in the tyrosine kinase inhibitor era
    Alshomar, Ahmad
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2022, 47 (02): : 81 - 87
  • [34] Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
    Castillo, Dan Ran
    Park, Daniel
    Mehta, Akhil
    Kaur, Simmer
    Nguyen, Anthony
    Akhtari, Mojtaba
    HEMATOLOGY REPORTS, 2022, 14 (01) : 45 - 53
  • [35] Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Zimu Gong
    Lan Zheng
    Zhenya Tang
    Zi Chen
    Wei Wang
    Shi Bai
    Guilin Tang
    L. Jeffrey Medeiros
    Shimin Hu
    Annals of Hematology, 2017, 96 : 1239 - 1239
  • [36] Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
    Takashi Hamada
    Noriyoshi Iriyama
    Hiromichi Takahashi
    Katsuhiro Miura
    Yoshihito Uchino
    Masaru Nakagawa
    Yoshihiro Hatta
    Masami Takei
    Clinical Drug Investigation, 2018, 38 : 813 - 818
  • [37] Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China
    Qian Jiang
    Robert Peter Gale
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 1549 - 1555
  • [38] Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
    D J DeAngelo
    Blood Cancer Journal, 2012, 2 : e95 - e95
  • [39] Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy
    Terao, Ryuta
    Nii, Mitsumaro
    Asai, Hiroko
    Nohara, Fumikatsu
    Okamoto, Toshio
    Nagaya, Ken
    Azuma, Hiroshi
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 756 - 760
  • [40] Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
    Hamada, Takashi
    Iriyama, Noriyoshi
    Takahashi, Hiromichi
    Miura, Katsuhiro
    Uchino, Yoshihito
    Nakagawa, Masaru
    Hatta, Yoshihiro
    Takei, Masami
    CLINICAL DRUG INVESTIGATION, 2018, 38 (09) : 813 - 818
12345